Actively Recruiting
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Led by Ankara University · Updated on 2026-02-27
50
Participants Needed
2
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating imaging techniques for patients with differentiated thyroid cancer who have undergone surgery and radioactive iodine therapy but show elevated serum thyroglobulin (Tg) and/or anti-thyroglobulin (ATg) levels during follow-up. The study compares a new imaging agent, F-18 Tetrafluoroborate (TFB) PET/CT, with the standard F-18 Fluorodeoxyglucose (FDG) PET/CT in detecting cancer lesions. F-18 TFB targets thyroid cancer cells through a mechanism similar to I-131 but has shown higher specificity in earlier studies. Participants receive F-18 TFB whole-body PET/CT scans as the investigational imaging method. This diagnostic test is assessed for its ability to detect lesions compared to standard methods. The study does not involve treatment drugs but focuses on imaging accuracy and diagnostic performance in this patient group. During the study, researchers will measure how well F-18 TFB PET/CT identifies cancer lesions and analyze its positivity rate. They will also study how imaging measurements relate to serum Tg and ATg levels. The main outcome is diagnostic accuracy measured over nine months after the first patient enrollment, with safety and performance monitored throughout the study.
CONDITIONS
Brief Title
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
- Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during follow-up
- Negative or equivocal I-131 whole-body scan findings
- Karnofsky Performance Status of 50 or higher (or equivalent ECOG/WHO performance status)
- Provide written informed consent
You will not qualify if you...
- Under 18 years of age
- Pregnant or breastfeeding
- Unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 9 months from enrollment
Participants undergo F-18-Tetrafluoroborate whole body PET/CT to evaluate lesion detection during follow-up.
1 visit (in-person)
Duration - Up to 9 months from enrollment
Participants are observed to assess diagnostic accuracy and correlation with serum markers after the PET/CT scan.
Periodic assessments depending on follow-up schedule
Trial Site Locations
Total: 2 locations
1
Ankara University Medical School Nuclear Medicine Department
Ankara, Ankara, Turkey (Türkiye), 06590
Actively Recruiting
2
Hacettepe University Medical School Nuclear Medicine Department
Ankara, Ankara, Turkey (Türkiye), 06590
Actively Recruiting
Research Team
M
Mine Araz, Assoc.Prof.Dr.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here